loading page

Association Between Influenza Vaccination and Reduced Risk of Acute Kidney Injury Among the Elderly
  • +2
  • Haerin Cho,
  • Eunsun Lim,
  • Hee-Jin Kim,
  • Na-Young Jeong,
  • Nam-Kyong Choi
Haerin Cho
Ewha Womans University
Author Profile
Eunsun Lim
Ewha Womans University
Author Profile
Hee-Jin Kim
Ewha Womans University
Author Profile
Na-Young Jeong
Ewha Womans University
Author Profile
Nam-Kyong Choi
Ewha Womans University

Corresponding Author:[email protected]

Author Profile

Abstract

Background: Several cases of renal complications including acute kidney injury (AKI) after influenza vaccination have been reported, but the association remains unproven. We evaluated the association between influenza vaccination and AKI occurrence among the Korean elderly in the 2018–2019 and 2019–2020 seasons. Methods: We used a large database that combined vaccination registration data from the Korea Disease Control and Prevention Agency and the claims data from the National Health Insurance Service. The study subjects were patients hospitalized with AKI for the first time following vaccination among those who received one influenza vaccine in the 2018–2019 or 2019–2020 season. Only those who were 65 or older at the date of vaccination were included in our study. We performed a self-controlled case series study in which the risk period was designated as 1 to 28 days after vaccination, and the observation period as each influenza season. We conducted sensitivity analyses with varied risk periods and observation periods. Results: A total of 16,713 and 16,272 AKI events were identified during each influenza season. The adjusted incidence rate ratio (aIRR) for AKI was 0.83 (95% confidence interval [CI]= 0.79–0.87) in the 2018–2019 season. The IRR of the 2019–2020 influenza vaccination was similar to the 2018–2019 season (aIRR=0.86; 95% CI=0.82–0.90). Sensitivity analyses showed similar results. Conclusions: We suggest that influenza vaccination is associated with a lower risk of AKI in the elderly over 65.
27 Feb 2024Submitted to Pharmacoepidemiology and Drug Safety
27 Feb 2024Submission Checks Completed
27 Feb 2024Assigned to Editor
01 Mar 2024Reviewer(s) Assigned
01 Apr 2024Review(s) Completed, Editorial Evaluation Pending
20 Jun 20241st Revision Received
20 Jun 2024Review(s) Completed, Editorial Evaluation Pending
22 Jun 2024Submission Checks Completed
22 Jun 2024Assigned to Editor
14 Jul 2024Editorial Decision: Revise Minor
17 Jul 20242nd Revision Received
17 Jul 2024Submission Checks Completed
17 Jul 2024Assigned to Editor
17 Jul 2024Review(s) Completed, Editorial Evaluation Pending
11 Aug 2024Editorial Decision: Revise Minor
13 Aug 20243rd Revision Received
13 Aug 2024Submission Checks Completed
13 Aug 2024Assigned to Editor
13 Aug 2024Review(s) Completed, Editorial Evaluation Pending
19 Aug 2024Editorial Decision: Accept